|
|
|
|
Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3
Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) (Formerly Lymphostat-B(R)) in Systemic Lupus Erythematosus ROCKVILLE, Maryland, July 1 /PRNewswire-USNewswire/ --...
|
|
|
Early Diagnosis and Treatment of Discoid Lupus Erythematosus
_ Early Diagnosis and Treatment of Discoid Lupus Erythematosus.
|
|
|
Novel DNA Vaccine Leads To Kidney Damage Prevention In Systemic Lupus Erythematosus Models, Universidad de Gua
' DNA vaccination using lupus autoantigens and interleukin-10 (IL-10, a cytokine that plays an important role in regulating the immune system) has potential as a novel therapy to induce antigen specific tolerance and may help to prevent...
|
|
|
Novel DNA Vaccine Leads To Kidney Damage Prevention In Systemic Lupus Erythematosus Models
DNA vaccination using lupus autoantigens and interleukin-10 (IL-10, a cytokine that plays an important role in regulating the immune system) has potential as a novel therapy to induce antigen specific tolerance and may help to prevent kidney...
|
|
|
Anxiety And Depression Lower Quality Of Life In Majority Of Systemic Lupus Erythematosus Patients
% of patients with systemic lupus erythematosus (SLE) suffer anxiety and depression which significantly affects both their physical and emotional quality of life (QoL), according to the results of a new study presented today at EULAR 2009,...
|
|
|
Hydroxychloroquine Use May Be Safe in Systemic Lupus Erythematosus
_ Hydroxychloroquine Use May Be Safe in Systemic Lupus Erythematosus.
|
|
|
Hydroxychloroquine Use May Be Safe in Systemic Lupus Erythematosus
_ Hydroxychloroquine Use May Be Safe in Systemic Lupus Erythematosus.
Abstracts in Hematology and Oncology:
Jun 15 2009 3:05PM
Matching: lupus erythematosus systemic
|
Find similar documents
|
|
|
|
Hydroxychloroquine Use May Be Safe in Systemic Lupus Erythematosus
_ Hydroxychloroquine Use May Be Safe in Systemic Lupus Erythematosus.
|
|
|
In Systemic Lupus Erythematosus Models, Novel DNA Vaccine Leads To Kidney Damage Prevention
Systemic Erythematosus Models, Novel DNA Vaccine Leads To Kidney Damage Prevention Medical Medical Medical Worldwide Search / Oncology hip Funny Useful Websites details of 26,000 UK specialists medical software Ask a Doctor and...
|
|
|
Active Biotech Presents Data regarding the 57-57 SLE Project at EULAR
Active Biotech (NASDAQ OMX Nordic: ACTI) has presented updated data from a concluded Phase Ib trial of the 57-57 SLE project at the 10th Annual Congress of the European League against Rheumatism (EULAR), an international event for...
|
|
|
Active Biotech Presents Data regarding the 57-57 SLE Project at EULAR
-- Active Biotech (NASDAQ OMX Nordic: ACTI) has presented updated data from a concluded Phase Ib trial of the 57-57 SLE project at the 10th Annual Congress of the European League against Rheumatism (EULAR), an international event for...
|
|
|
Active Biotech Presents Data regarding the 57-57 SLE Project at EULAR
Active Biotech (NASDAQ OMX Nordic: ACTI) has presented updated data from a concluded Phase Ib trial of the 57-57 SLE project at the 10th Annual Congress of the European League against Rheumatism (EULAR), an international event for...
|
|
|
Active Biotech Presents Data regarding the 57-57 SLE Project at EULAR
- Active Biotech (NASDAQ OMX Nordic: ACTI) has presented updated data from a concluded Phase Ib trial of the 57-57 SLE project at the 10th Annual Congress of the European League against Rheumatism (EULAR), an international event for...
|
|
|
Active Biotech: Active Biotech Presents Data regarding the 57-57 SLE Project at EULAR
SOURCE: Active Biotech LUND, SWEDEN--(Marketwire - June 11, 2009) - Active Biotech (NASDAQ OMX Nordic: ACTI) has presented updated data from a concluded Phase Ib trial of the 57-57 SLE project at the 10th Annual Congress of the European...
|
|
|
Active Biotech Presents Data regarding the 57-57 SLE Project at EULAR
The patients in the Phase Ib trial were treated daily for 12 weeks with 57-57.The maximum tolerable dose (MTD) was, as earlier communicated, defined at 4.5 mg/day. The overall safety profile throughout the study was favorable. In a...
|
|
|
Active Biotech Presents Data regarding the 57-57 SLE Project at EULAR
LUND, SWEDEN -- (MARKET WIRE) -- 06/11/09 -- Active Biotech (NASDAQ OMX Nordic: ACTI) has presented updated data from a concluded Phase Ib trial of the 57-57 SLE project at the 10th Annual Congress of the European League against Rheumatism ...
|
|
|
Active Biotech Presents Data regarding the 57-57 SLE Project at EULAR
Active Biotech (NASDAQ OMX Nordic: ACTI) has presented updated data from a concluded Phase Ib trial of the 57-57 SLE project at the 10th Annual Congress of the European League against Rheumatism (EULAR), an international event for...
|
|
|
Active Biotech Presents Data regarding the 57-57 SLE Project at EULAR
-Active Biotech (NASDAQ OMX Nordic: ACTI) has presented updated data from a concluded Phase Ib trial of the 57-57 SLE project at the 10th Annual Congress of the European League against Rheumatism (EULAR), an international event for...
|
|
|
Human Genome Sciences reveals Positive Long-Term Data for BENLYSTA in Patients With Active Systemic Lupus Eryt
AM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Human Genome Sciences Inc.(HGSI: News ) announced the presentation of results from a long-term Phase 2 continuation trial showing that BENLYSTA (belimumab, formerly LymphoStat-B) was...
|
|
|
UPDATE 1-Human Genome says lupus drug shows positive results
SAYS ENCOURAGING RESULTS FROM MID-STAGE LUPUS DRUG TRIAL * Says no serious adverse events seen * Shares soar as much as 29 percent pre-market June 11 (Reuters) - Human Genome Sciences Inc said its lupus drug continued to show positive...
|
|
|
Human Genome Sciences Reveals Positive Trial Results Of Lupus Drug, Shares Up - Update
AM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Thursday, at the 2009 Congress of the European League Against Rheumatism, or EULAR, Human Genome Sciences Inc.(HGSI: News ) presented positive results from a long-term phase II continuation...
|
|
|
Research and Markets: The Immune/Inflammatory Pipeline - A Strategic Review
gaining access to niche indications.Key Topics Covered: Executive Summary Strategic Considerations Stakeholder Implications Introduction The Immune/Inflammatory Disease Pipeline Emerging Agents Targeting Diseases with Unmet Needs...
|
|
|
DNA-Like Drugs Target Systemic Lupus Erythematosus
A potential new treatment for systemic lupus erythematosus (SLE) has been demonstrated in a mouse model of this chronic autoimmune syndrome.Investigators from the University of Iowa (Ames, USA) and at Boston University School of Medicine ...
|
|
|
Human Genome Sciences - Racing To Cure Lupus
(RTTNews) - It has been over 50 years since the FDA approved a drug for lupus, a chronic autoimmune disease, in which the body's immune system attacks its own cells and tissues, damaging the organs.The disease affects various body parts,...
|
|
|
Human Genome Sciences - Racing To Cure Lupus
(RTTNews) - It has been over 50 years since the FDA approved a drug for lupus, a chronic autoimmune disease, in which the body's immune system attacks its own cells and tissues, damaging the organs.The disease affects various body parts,...
|
